Skip to content

Effects of Vivideal multi-component exercise on physical function, cognitive status, and mental health of Patients with neurocognitive disorders

Effects of Vivideal multi-component exercise on physical function, cognitive status, and mental health of Patients with neurocognitive disorders

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100050601
Enrollment
Unknown
Registered
2021-09-01
Start date
2021-10-01
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurocognitive disorder

Interventions

Experimental group:VIVIFRAIL Multicomponent exercise

Sponsors

The First Affiliated Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 60 years, and expected hospital stay >= 12 weeks; 2. Able to use verbal or non-verbal guidance to cooperate with the intervention plan; 3. Able to walk independently for 10 meters or more, including the use of assistive devices; 4. The ability to sit unassisted in a chair; 5. Define MCI according to the criteria of Albert et al: (1) Subjective cognitive complaints; (2) Objective cognitive impairment unrelated to delirium, including four cognitive domains of memory, executive function, attention, and language, using one or more implementation item tests, such as the Montreal Cognitive Score 13-24; (3) Retention of activities of daily living, with a score of > 14 on the Lawton-Brody Organic Activities of Daily Living (IADL) scale; (4) No dementia according to the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders or the Global Clinical Dementia Score (CDR) <= 0.5. 6. Patients with early and mid-stage dementia diagnosed using the Diagnostic and Statistical Manual of Mental Disorders (DSM-V TR).

Exclusion criteria

Exclusion criteria: 1. Participants with severe depression, schizophrenia, severe anxiety or substance abuse; 2. Current Parkinson's disease or any neurological disease with residual movement impairment (eg stroke with movement impairment), active musculoskeletal disease (eg severe lower extremity osteoarthritis) or history of knee/hip replacement under clinical evaluation affect gait performance; 3. Intention to participate in other clinical trials within the same time period; 4. Actively participate in an exercise program of aerobic exercise or resistance exercise program 2 or more times per week in the past 6 months; 5. Moderate to severe insufficiency of heart, lung, liver and kidney functions; 6. Uncontrolled hypertension, diabetes; 7. Severe uncorrected visual or hearing impairment; 8. Advanced or severe dementia.

Design outcomes

Primary

MeasureTime frame
Short-Physical Performance Battery;

Secondary

MeasureTime frame
six meters walking speed;Time up and go test;Tinetti Balance and Gait Assessment Scale;Verbal fluency test;The Serial Sevens Test;30-second chair stand test;9-item Patient Health Questionnaire;Simple Mental Condition Checklist;Caregiver Burden Questionnaire;International Fall Efficacy Scale-I;health status questionnaire;6 minute walk test;daily living ability;

Countries

China

Contacts

Public ContactJin Qun

Quzhou Third Hospital

505339547@qq.com+86 15068960450

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026